Here, we show that PXR carries out its noncanonical anti-apoptotic functions in colon cancer by reducing the binding of p53 to its target gene promoters, thereby inhibiting the tumor-suppressive activity of p53. This evidence concerns the gene NR1I2 and neoplasm.